Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.
Type:
Grant
Filed:
April 19, 2019
Date of Patent:
January 21, 2025
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
January 14, 2025
Assignees:
ABL BIO INC., I-MAB BIOPHARMA US LIMITED
Inventors:
Eunyoung Park, Yangsoon Lee, Hyejin Chung, Eunsil Sung, Jiseon Yoo, Minji Park, Yong-Gyu Son, Hyoju Choi, Eunjung Kim, Jaeho Jung, Weon-Kyoo You, Sang Hoon Lee, Lei Fang, Wenqing Jiang
Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.
Type:
Grant
Filed:
December 18, 2023
Date of Patent:
January 14, 2025
Assignee:
SANOFI
Inventors:
Gerald Beste, Yanik Bruynooghe, Klervi Desrumeaux, Jennifer Kuehn, Charlotte Lahoute, Rami Lissilaa, Alessandro Masiero, Sevim Oezguer Bruederle, Benjamin Suratt, Emmanuelle Vigne, Jessica Voss
Abstract: Described herein are compositions comprising subsets of monocyte having distinct functional properties and methods for using the same to treat infectious disease.
Type:
Grant
Filed:
November 12, 2021
Date of Patent:
January 14, 2025
Assignees:
The General Hospital Corporation, President and Fellows of Harvard College
Abstract: The present invention provides novel human fins related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and/or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3×CD3 antibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention.
Type:
Grant
Filed:
September 11, 2019
Date of Patent:
January 14, 2025
Assignees:
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS, EBERHARD KARLS UNIVERSITAT TUBINGEN
Inventors:
Gundram Jung, Helmut Salih, Fabian Vogt, Latifa Zekri-Metref, Martin Pflügler, Isabelle Ehnes
Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.
Abstract: The present disclosure relates to biotechnology and provides antibodies that specifically bind to IL-5R?. The disclosure also relates to DNA encoding the antibodies, the corresponding expression vectors and methods of production thereof, as well as methods of treatment using the antibodies.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
December 24, 2024
Inventors:
Ekaterina Vladimirovna Sofronova, Aleksei Konstantinovich Misorin, Aleksandr Nikolaevich Doronin, Timofey Aleksandrovich Nemankin, Aleksandra Aleksandrovna Sozonova, Galina Stepanovna Zhirivskaia, Sergey Aleksandrovich Legotsky, Anna Konstantinovna Vladimirova, Alina Valerevna Beliasnikova, Mariia Aleksandrovna Shchemeleva, Pavel Andreevich Iakovlev, Valery Vladimirovich Solovyev, Elena Andreevna Krendeleva, Natalia Evgenevna Pestova, Dmitry Valentinovich Morozov
Abstract: Disclosed is an isolated binding protein including a cardiac troponin I (cTnI) antigen binding domain, and preparation and a use and the like of the binding protein. The antigen binding domain includes at least one complementarity determining region selected from an amino acid sequence defined in this article, or has at least 80% sequence identity with the complementarity determining region of the amino acid sequence and has KD?9.96×10?8 mol/L affinity with cTnI. The binding protein may be used in the detection field of the cTnI protein.
Abstract: Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).
Type:
Grant
Filed:
September 20, 2019
Date of Patent:
December 17, 2024
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), NANTES UNIVERSITE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Abstract: Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjögren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.
Abstract: Provided is a composition for cytotoxic T cell depletion, comprising an anti-LAG-3 antibody or a binding fragment thereof having the properties described in (i) to (iii) below: (i) having in vitro ADCC activity; (ii) reducing, in a low fucose form, the number of LAG-3 positive cells in vivo; and (iii) binding to activated human T cells. Also provided are methods for depleting cytotoxic T cells using the disclosed anti-LAG-3 antibody or binding fragment thereof.
Abstract: A cyclic polypeptide, derivative or analogue thereof, comprising an amino acid sequence derived from the C-terminus of acetylcholinesterase (AChE), or a truncation thereof.
Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.
Type:
Grant
Filed:
March 25, 2021
Date of Patent:
November 12, 2024
Inventors:
Omoniyi Adedokun, Daphne Chan, Yang Chen, Philippe Szapary
Abstract: The present disclosure provides an antibody for inducing immune tolerance, an induced lymphocyte, and a cell therapy agent therapeutic method using the induced lymphocyte. Specifically, the present disclosure provides an antibody that inhibits the interaction between CD80 and/or CD86 expressed on the surface of a certain cell and CD28 expressed on the surface of another cell, and substantially does not induce immune activation-induced cytokines. In a specific embodiment, the Fc portion of the antibody substantially does not produce the immune activation-induced cytokines.
Abstract: Monoclonal antibodies that bind, such as specifically bind, blood protein factor XII (FXII) are described. The monoclonal antibodies (including antigen-binding fragments thereof) are capable of forming immune complexes with human FXII and inhibiting FXII activity, resulting in safe anti-inflammatory and anti-thrombotic effects.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
November 5, 2024
Assignees:
Oregon Health & Science University, Aronora, Inc.
Inventors:
Michael Wallisch, Andras Gruber, Erik I. Tucker, Christina U. Lorentz
Abstract: Provided is a MART-1 (27-35) epitope-specific T cell receptor, comprising an ? chain and a ? chain. The ? chain comprises three complementary determining regions, respective sequences thereof being positions 61-66, positions 84-89, and positions 124-136 of SEQ ID No. 3. The ? chain comprises three complementary determining regions, respective amino acid sequences thereof being positions 46-50, positions 68-73, and positions 112-125 of SEQ ID No. 4. A T cell expressing the TCR can effectively recognize a MART-1 (27-35) epitope polypeptide supported on a T2 cell and secrete IFN-?, thereby demonstrating the functionality of the receptor. Use of the TCR with a relevant drug target allows for effective drug development.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
November 5, 2024
Assignee:
BGI SHENZHEN
Inventors:
Fei Wang, Chengchi Chao, Bo Li, Yong Hou, Yuelu Yin, Shilei Wang, Kun Duan
Abstract: Provided are anti-human Tim-3 IgV domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.
Abstract: Materials and methods for using polypeptides containing fragments and variants of the antibody(ies) or portion(s) thereof that bind CD25 to treat cancer alone or in combination with other anti-neoplastic agents.
Type:
Grant
Filed:
August 22, 2022
Date of Patent:
October 29, 2024
Assignee:
iBio, Inc.
Inventors:
Dillon Phan, Martin Brenner, Brian Berquist, Peter Kipp, Tam Phuong, Kevin Babilonia, Tom Hsu, Lufei Hu, James Talmage Taylor, Jr., Cory Schwartz